Tagged Articles

diabetes medication 18 articles

Takeda faces damning testimony in Actos bladder cancer lawsuit

Upjohn Co. allegedly backed out of development of the type 2 diabetes drug Actos in 1993 because of safety concerns, according to court testimony. However, Takeda Pharmaceuticals, the drug’s maker, urged Upjohn to say that it was backing away from the project because it didn’t believe the drug would be effective in the treatment of diabetes, an expert witness for the plaintiffs said. Randall Tackett, a pharmacologist and toxicologist at the University of Georgia, testified on behalf of plaintiff Frances Wisniewski, who is suing Takeda over claims that the Japanese drug maker’s diabetes medication Actos caused her to develop bladder cancer, ... Read More

Waistline measurement can indicate type 2 diabetes risk

Want to know if you are at risk for type 2 diabetes? Then whip out your tape measure, says Public Health England. Waistlines larger than 40 inches in men or 35 inches in women indicate a “very high risk” of developing the chronic disease, the agency warns. Men with a 40-inch waist are five times more likely to develop type 2 diabetes and women with 35-inch waistlines were three times more likely to develop the disease compared to those with slimmer waistlines. Even waistlines three to four inches smaller than 40 or 35 inches for men and women, respectively, puts ... Read More

Healthier diabetics may fare better with less aggressive approach to disease management

Type 2 diabetes drugs could be doing patients more harm than good, especially older diabetics, a new study shows. The research, published in a recent edition of the Journal of the American Medical Association Internal Medicine, addressed how current guidelines for diabetes management were serving patients. Currently, diabetes management involves intensifying treatment until the patient’s blood sugar level has evened out. Researchers say this method appears to cause more negative impacts to patients than positive ones. “For people with type 2 diabetes, the goal of managing blood sugar levels is to prevent associated diabetes complications, such as kidney, eye and ... Read More

European Union approves new combination treatment for type 2 diabetes

European Union drug regulators have approved a new combination pill to treat type 2 diabetes. Vokanamet combines the new diabetes drug Invokana with the standard treatment metformin. The new treatment is made by Johnson & Johnson and will be marketed in Europe by Janssen-Cliag International. The active ingredient in Invokana is canagliflozin, which is in a class of diabetes medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs are designed to help reduce blood sugar levels by preventing the reabsorption of glucose from the kidneys back into the blood, and allows glucose to be excreted in the urine. The U.S. ... Read More

Participants sought for study on long-term effects of type 2 diabetes drugs

People between 30 and 70 years of age diagnosed with type 2 diabetes within the past five years who take no medication to treat the chronic condition are being sought for a study evaluating long-term effectiveness of diabetes drugs. The study is being conducted at 37 sites across the country and aims to recruit about 5,000 participants. The study, called G.R.A.D.E. – the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study – will compare four medications, each combined with metformin. The National Institute of Diabetes, along with Digestive and Kidney Diseases of the National Institutes of Health, is funding ... Read More

Researcher looking for volunteers to test common type 2 diabetes drugs

A researcher at the Washington University School of Medicine in St. Louis, Mo., is looking for volunteers for a major type 2 diabetes research project to determine which of four popular drugs is the most effective at treating the chronic disease long term. Type 2 diabetes is a lifelong condition. People with the disease have high levels of sugar in the blood. They typically require medication to regulate their blood sugar levels. The study will also test a new delivery system – a small, toothpick-sized implant designed to deliver medication for up to six months. People who are accepted into ... Read More

Byetta may improve Parkinson’s symptoms but side effects are concerning

The type 2 diabetes drug Byetta may help improve Parkinson’s disease symptoms in diabetics, a small study published in the Journal of Clinical Investigation suggests. The study involved 44 people, 20 of whom were regularly given injections of Byetta. The remaining 24 were given a placebo. The patients were followed for 14 months. Patients who were given Byetta injections showed a mean improvement of symptoms of 2.7 points on the MDS-UPDRS scale, a process to measure progression of Parkinson’s disease. The group of patients who were given a placebo declined 2.2 points on the scale. Researchers noted that the findings ... Read More

FDA panel votes to loosen restrictions on Avandia despite heart attack risk

An advisory panel to the Food and Drug Administration (FDA) voted to recommend that the severe restrictions the agency placed on the type 2 diabetes drug Avandia be loosened. The vote was far from unanimous, with five members voting to keep the tight restrictions on Avandia and one member (the consumer representative) calling for the withdrawal of the drug. Avandia, also known as rosiglitazone, was a top-selling diabetes medication until, in 2010, the FDA placed severe restrictions on the medication based on studies that showed the people who took the medication were at greater risk of dying from a heart ... Read More

Novo Nordisk testing higher doses of Victoza as weight loss drug for obese diabetics

Novo Nordisk is hoping data from a phase III trial involving a higher dosage of its type 2 diabetes drug Victoza (liraglutide) will show it can help overweight and obese people with the chronic disease lose weight. The first of three studies in the pharmaceutical company’s SCALE clinical program showed promising results. Patients given a high (3mg) dose achieved a 6 percent reduction in weight compared to a 2 percent reduction in patients taking a placebo. Victoza is already approved in 1.8 mg dosage, and previous studies have shown the drug can reduce weight in patients by 5 percent. The ... Read More

Cost of diabetes rising as number of diabetics increases

The cost of diabetes rose more than 40 percent during the past five years, however the per-patient cost has remained roughly flat, according to new research that will be published in the April issue of Diabetes Care. The study, commissioned by the American Diabetes Association, estimated that diabetes cost the nation $245 billion in 2012, compared to $174 billion in 2007. Comparatively, an estimated 22.3 million people were diagnosed with the disease in 2012, compared to about 17.5 million in 2007. John Anderson, president of medicine and science for the American Diabetes Association, said the data shows the rising cost ... Read More